Came across this during my 'cooling off' perioid last week.
It highlights how many pharmaceutical companies complain of one anothers marketing tactics.
Seeing as my major gripe is with GlaxoSmithKline I'll show you how they like to be top dog and how they like to 'play the game' with their competitors.
It makes interesting reading and shows us all how GlaxoSmithKline don't like it up them and the lengths they will go to - to protect their products.
It's no wonder they spend so much on their lawyers and PR machine. Before we know it they will be trying to convince the powers that be that we need to end punitive damages!
DECISIONS CONCERNING MARKETING OF PRESCRIPTION-ONLY MEDICINES - YEAR 2005
9/2005 Flamenco performance at a training event
GlaxoSmithKline made a complaint about programme of a training event arranged byAstraZeneca. Along with the scientific program and the following dinner the programmeincluded music and a flamenco performance. Recorded music can be played as background musicbut the flamenco performance was beyond the hospitality allowed in the Code for the Marketing of Medicinal Products. AstraZeneca was requested to abstain from incorrect marketing andimposed a sanction payment of 2,000 euros.
GlaxoSmithKline made a complaint about Actos advertisement by Eli Lilly Finland Ab. Inthe advertisement it could be said that Actos is effective also against lipids because the claim wassupported by scientific evidence and the SPC, the actual indication of the product, type II diabetes, was clearly brought out and controlling of lipids is of relevance to these patients. The advertisement was not misleading in the sense that it would have suggested Actos’ indications to include lowering cholesterol and therefore the complaint was dismissed.
GlaxoSmithKline made a complaint about Symbicort advertisement in a magazine byAstraZeneca. The advertisement gave an impression that Symbicort could be used as a treatment also for acute asthma attacks, which was not in line with indications included in Symbicort’s SPC. The advertisement was misleading also in a sense that it suggested Symbicort treatment to be effective in every case. AstraZeneca Oy was requested to abstain from incorrect marketing and imposed a sanction payment of 10 000 euros.
Decision in July 26th 2005, advertisement in “Arki ja allergia” book
GlaxoSmithKline made a complaint about AstraZeneca Oy’s prescription drug SymbicortTurbuhaler’s advertisement in a book about allergies that was targeted to consumers. As Inspection Board had already earlier taken up the matter on its own initiative and as consequence AstraZeneca had been requested to abstain from incorrect marketing and imposed a sanction payment of 15 000 euros (Decision 13/2005 by Supervisory Commission is about AstraZeneca complaint in that matter), the complaint was dismissed.
Decision in December 21st 2005, Internet pages http://www.glaxosmithkline.fi/
Inspection Board took up GlaxoSmithKline homepages on Internet under examination on its own initiative. The pages contained press releases which marketed prescription drug Havrix directly to consumers, as the information in them was not equally covering all treatment options as required by the Code when disease awareness campaigns are carried out. In addition there was another press release on the pages that was found as disguised advertising of a prescription drug to consumers. GlaxoSmithKline was requested to abstain from incorrect marketing and imposed a sanction payment of 5 000 euros.
Decision in January 4th 2005, Seretide
AstraZeneca made a complaint about GlaxoSmithKline marketing which according toAstraZeneca did not comply with an agreement between the parties to abstain from incorrect marketing activities. Inspection Board found that the parties had agreed not to refer to certain study results in marketing materials before these results were published. In this case the study in question had later been published as an article in a scientific journal and thus after publication it could be referred to in marketing materials. The complaint was dismissed
Decision in May 25th 2005, Seretide
AstraZeneca Oy made a complaint about Seretide newspaper advertisement by GlaxoSmithKline. In the advertisement an expression from the cited clinical study was misleadingly translated from “totally controlled asthma” into “living without symptoms”. Absence of symptoms was also emphasized too categorically. GlaxoSmithKline was requested to abstain from incorrect marketing and imposed a sanction payment of 8 000 euros. (Articles of the EFPIA Code suitable for the case: 4)
THE SUPERVISORY COMMISSION FOR THE MARKETING OF MEDICINAL PRODUCTS: SUMMATION OF DECISIONS CONCERNING MARKETING OF PRESCRIPTION-ONLY MEDICINES - YEAR 2005 can be downloaded HERE
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON